Syndax Pharmaceuticals, Inc. (SNDX) Can’t Be More Safe. Trades Significantly Higher

December 7, 2017 - By Marguerite Chambers

The stock of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a huge mover today! The stock increased 2.28% or $0.18 during the last trading session, reaching $8.06. About 222,560 shares traded or 31.05% up from the average. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.09% since December 7, 2016 and is uptrending. It has underperformed by 9.61% the S&P500.
The move comes after 8 months positive chart setup for the $196.58M company. It was reported on Dec, 7 by We have $8.46 PT which if reached, will make NASDAQ:SNDX worth $9.83M more.

Analysts await Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report earnings on March, 1. They expect $-0.94 earnings per share, down 59.32 % or $0.35 from last year’s $-0.59 per share. After $-0.68 actual earnings per share reported by Syndax Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 38.24 % negative EPS growth.

More notable recent Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news were published by: which released: “Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and …” on May 08, 2017, also with their article: “Syndax Pharmaceuticals’ (SNDX) CEO Briggs Morrison on Q2 2017 Results …” published on August 11, 2017, published: “Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology …” on November 11, 2017. More interesting news about Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) were released by: and their article: “Syndax Locks In To Tumor Escape” published on June 29, 2017 as well as‘s news article titled: “Syndax Pharmaceuticals’ (SNDX) CEO Briggs Morrison on Q3 2017 Results …” with publication date: November 08, 2017.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $196.58 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.